151 related articles for article (PubMed ID: 17538163)
1. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Agulnik M; da Cunha Santos G; Hedley D; Nicklee T; Dos Reis PP; Ho J; Pond GR; Chen H; Chen S; Shyr Y; Winquist E; Soulieres D; Chen EX; Squire JA; Marrano P; Kamel-Reid S; Dancey J; Siu LL; Tsao MS
J Clin Oncol; 2007 Jun; 25(16):2184-90. PubMed ID: 17538163
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.
Thomas F; Rochaix P; Benlyazid A; Sarini J; Rives M; Lefebvre JL; Allal BC; Courbon F; Chatelut E; Delord JP
Clin Cancer Res; 2007 Dec; 13(23):7086-92. PubMed ID: 18056187
[TBL] [Abstract][Full Text] [Related]
4. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Felip E; Rojo F; Reck M; Heller A; Klughammer B; Sala G; Cedres S; Peralta S; Maacke H; Foernzler D; Parera M; Möcks J; Saura C; Gatzemeier U; Baselga J
Clin Cancer Res; 2008 Jun; 14(12):3867-74. PubMed ID: 18559607
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
Rojo F; Gracias E; Villena N; Cruz T; Corominas JM; Corradino I; Cedeño M; Campas C; Osorio M; Iznaga N; Bellosillo B; Rovira A; Marsoni S; Gascon P; Serrano S; Sessa C; Crombet T; Albanell J
Clin Cancer Res; 2010 Apr; 16(8):2474-82. PubMed ID: 20371675
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Tan AR; Yang X; Hewitt SM; Berman A; Lepper ER; Sparreboom A; Parr AL; Figg WD; Chow C; Steinberg SM; Bacharach SL; Whatley M; Carrasquillo JA; Brahim JS; Ettenberg SA; Lipkowitz S; Swain SM
J Clin Oncol; 2004 Aug; 22(15):3080-90. PubMed ID: 15284258
[TBL] [Abstract][Full Text] [Related]
7. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
8. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
[TBL] [Abstract][Full Text] [Related]
9. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
10. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.
Calvo E; Malik SN; Siu LL; Baillargeon GM; Irish J; Chin SF; Santabarbara P; Kreisberg JI; Rowinsky EK; Hidalgo M
Ann Oncol; 2007 Apr; 18(4):761-7. PubMed ID: 17317676
[TBL] [Abstract][Full Text] [Related]
11. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
Lee Y; Shim HS; Park MS; Kim JH; Ha SJ; Kim SH; Cho BC
Clin Cancer Res; 2012 Mar; 18(6):1760-8. PubMed ID: 22271877
[TBL] [Abstract][Full Text] [Related]
12. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE
J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
Siu LL; Soulieres D; Chen EX; Pond GR; Chin SF; Francis P; Harvey L; Klein M; Zhang W; Dancey J; Eisenhauer EA; Winquist E; ;
J Clin Oncol; 2007 Jun; 25(16):2178-83. PubMed ID: 17538162
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
15. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.
Young RJ; Rischin D; Fisher R; McArthur GA; Fox SB; Peters LJ; Corry J; Lim A; Waldeck K; Solomon B
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1230-7. PubMed ID: 21467228
[TBL] [Abstract][Full Text] [Related]
16. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.
Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
J Surg Res; 2007 Nov; 143(1):20-6. PubMed ID: 17950068
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Malik SN; Siu LL; Rowinsky EK; deGraffenried L; Hammond LA; Rizzo J; Bacus S; Brattain MG; Kreisberg JI; Hidalgo M
Clin Cancer Res; 2003 Jul; 9(7):2478-86. PubMed ID: 12855621
[TBL] [Abstract][Full Text] [Related]
18. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation.
Muller S; Su L; Tighiouart M; Saba N; Zhang H; Shin DM; Chen Z
Cancer; 2008 Jul; 113(1):97-107. PubMed ID: 18473353
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.
Bontognali S; Pless M; Brutsche MH; Fischer C; Rochlitz C; Buess M
Onkologie; 2013; 36(4):161-6. PubMed ID: 23548963
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
